Xtract One Technologies (XTRA) Wins ~$1M Willis ISD Contract for 15 Systems

Starboard Value has acquired a stake in Solstice Advanced Materials (SOLS) and is pushing for $100M in cost cuts, focusing on core businesses. The move follows Solstice's abandoned $14.5B acquisition of Element Solutions, which faced investor scrutiny. Starboard sees growth potential in Solstice's nuclear operations due to rising AI-driven electricity demand. Solstice shares surged post-spinoff but fell after the failed deal.

Morgan Stanley upgraded Amazon to a top pick, raising its price target to $350 from $335, citing AWS growth, higher margins, and AI-driven catalysts. AWS revenue growth forecasts were increased to 47% in 2027 and 42% in 2028, driven by Nvidia GPU deployments. Capital spending forecasts were also raised. Amazon's Q3 results are due on 29 October.

SpaceX (SPCX) will face its largest stock lockup expiration on Oct. 22, with 1.3 billion shares eligible for sale. The company has had mixed reactions to previous lockup expirations. SpaceX's stock has climbed 27% since Aug. 6, but its valuation at 200x forward earnings raises concerns. Performance will depend on Q3 results and market reaction to the unlock.

Metis TechBio has signed a delivery deal with Eli Lilly worth up to $1.1 billion. The agreement highlights the growing focus on AI in the pharmaceutical sector to reduce costs and development timelines. Metis TechBio's stock has seen a 5-day change of +6.62% and a year-to-date change of -10.04%.

BHP Group reported a 19% drop in copper production due to Chilean storms and lower ore grades, but maintained annual guidance. The company has a 4.24% dividend yield, though its stock is 31.0% overvalued according to GF Value™. BHP's GF Score™ is 72/100, reflecting strong financials and profitability but weak growth. Insiders have sold shares, and guru activity is mixed.

IDEAYA Biosciences (IDYA) reported positive clinical trial data for Darovasertib in treating uveal melanoma, showing improved overall survival and tumor shrinkage. The drug is being evaluated in three trials, with plans to submit an NDA by the end of 2026. IDYA's stock closed up 2.92% at $33.81.